Long-term follow-up data from the TRANSFORM trial reveals that Breyanzi, a chimeric antigen receptor T-cell (CAR T) therapy, continues to provide event-free survival and durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL) who received treatment in the second line.

Subgroup analysis from the TRANSCEND NHL 001 trial demonstrates Breyanzi’s consistent clinical benefit in mantle cell lymphoma (MCL) patients, irrespective of prior treatment lines. This finding suggests the potential for earlier Breyanzi use in MCL treatment.

Additionally, data from a subgroup analysis of the TRANSCEND FL trial indicates that Breyanzi exhibits consistent efficacy and a favorable safety profile in relapsed or refractory follicular lymphoma (FL) patients, regardless of bridging therapy. This reinforces Breyanzi’s distinct characteristics in treating FL.

These studies underscore the transformative potential of Breyanzi in various lymphoma subtypes. Its clinically significant outcomes and demonstrated efficacy across a wide range of B-cell malignancies position it as a potentially definitive therapy.

The FDA recently accelerated the approval of Breyanzi for patients with relapsed or refractory FL who have undergone two or more prior lines of systemic treatment. Approval has also been granted for patients with relapsed or refractory MCL who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.

Important Safety Information

Breyanzi carries boxed warnings for the following potential adverse events:

• Cytokine Release Syndrome (CRS)
• Neurologic Toxicities
• Secondary Hematological Malignancies

Source link: http://www.businesswire.com/news/home/20240531469274/en/Bristol-Myers-Squibb%E2%80%99s-Breyanzi-Demonstrates-Clinically-Meaningful-Outcomes-Across-Broad-Range-of-B-Cell-Malignancies-in-New-Data-Presented-at-2024-ASCO%C2%AE-Annual-Meeting

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.